Section 5 of 6
Economic information and modeling report
17 evidence topics · 15 sources
Modeling overview
Summary: sponsor price and revenue statements
The sponsor states that the price of DT120 ODT has not been established. On its third quarter 2026 earnings call, the sponsor stated a commercial pricing corridor of $30,000 to $75,000 per treatment course, based on preliminary feedback from payers on the interventional psychiatry market, and said the corridor would narrow with further payer discussions. In the sponsor's 2026 Investor and Analyst Day presentation, payers name Spravato as the primary price analog, expect FDA-approved psychedelic treatments to be covered, and expect to manage use with prior authorization. The sponsor's 2026 corporate presentation combines 2 patients per month (24 per year), ~4,000 interventional psychiatry clinics (about half of the estimated Spravato REMS sites), and 100K patients treated into a $5B potential gross revenue opportunity, assuming the midpoint of the Spravato surrogate pricing range.
Summary: monitoring-session coding and costs
The sponsor describes a single-visit model reimbursed for the full session; each pivotal dosing session requires 8 hours of monitoring and clearance of the end-of-session checklist, and the sponsor states that existing coding systems could potentially be applied or changed, with reimbursement and coding not yet established. CPT codes 0820T, 0821T, and 0822T describe continuous in-person monitoring and intervention during psychedelic medication therapy, each hour, by a first physician or other qualified health care professional, a concurrent second one, and clinical staff under the direction of a physician or other qualified health care professional. For esketamine, CMS created HCPCS codes G2082 and G2083, effective January 1, 2020 on an interim final basis; G2082 covers an office visit with up to 56 mg of esketamine and 2 hours of post-administration observation, with supply inputs priced at $590.02 for 56 mg and $885.02 for 84 mg.
Summary: analog economic evaluations
ICER's esketamine report used a base-case price of $295 per 28 mg device, estimated an incremental cost-effectiveness ratio of approximately $198,000 per QALY versus no additional treatment, assigned a CPT 99214 visit to each dose for the 2-hour observation, and estimated that 16% of eligible patients could be treated at list price within its $819 million threshold. A separate cost-effectiveness analysis attributed most of the incremental cost to esketamine itself ($16,352), with smaller contributions from physician and medical assistant services ($2,062) and patient time ($2,074), with base case ratios of $237,111/QALY (societal) and $242,496/QALY (healthcare sector). ICER rated the evidence for MDMA-assisted psychotherapy insufficient and used a $10,000 placeholder per course; its micro-costing table lists three 8-hour MDMA sessions (CPT 90837, two therapists) with a cost per session of $1,177 and a total of $7,059; 1.91% of eligible patients could be treated over five years within $735 million per year, and the average annual budget impact per patient was $21,635 in Year one, with cumulative net annual costs of $47,677 per patient in Year five.
Summary: population and burden inputs
The sponsor's funnel counts 50 million U.S. adults with GAD or MDD, 26 million diagnosed, 13 million treated with prescription drugs, and 4.2 million failed by two or more prescription treatments. In the 2022 US National Health and Wellness Survey (N=75,261), adjusted total direct costs were $11,711 for diagnosed and $18,045 for undiagnosed GAD versus $9,190 without GAD, and adjusted indirect costs were $7,507, $7,805, and $6,532 (all comparisons p<0.01). In the 2009 and 2010 Medical Expenditure Panel Survey, annual incremental healthcare expenditure for anxiety disorders was $1657.52 per person, approximately $33.71 billion in total in 2013 US dollars. Among 10,275 patients in a large US health insurance database who started pharmacotherapy for GAD between 2003 and 2007, mean total healthcare costs rose from $4812 before treatment to $7182 during follow-up (p < 0.01). In a MindMed-funded survey of 20 payers covering 130.3 million lives, 40% believed GAD was not a major budgetary concern for their plan, and 70% expected the number of diagnosed individuals seeking reimbursement to increase within 3 years.
Payer pricing corridor: $30,000 to $75,000 per treatment course, November 2026
Annual price range modeled on Spravato as surrogate, January 2026 and May 2026, superseded in November 2026
Revenue opportunity per 100,000 patients treated: November 2026 corporate presentation
Payer insights on pricing and access: sponsor market research, April 2026
Session coding and reimbursement: sponsor statement
Monitoring-session codes for psychedelic medication therapy: CPT Category III codes 0820T to 0822T
Medicare codes for an observed esketamine session: HCPCS G2082 and G2083
ICER review of MDMA-assisted psychotherapy for PTSD: evidence rating and placeholder price
ICER review of MDMA-assisted psychotherapy for PTSD: session costs
| Resource | Resource use (number) | CPT code | Number of therapists | Cost per session | Total |
|---|---|---|---|---|---|
| Psychiatric diagnosis interview examination | “1” | “90792” | “2” | “$219” | “$438” |
| 90 min preparation session | “3” | “90837” | “2” | “$221” | “$1,324” |
| 8-hour MDMA session | “3” | “90837” | “2” | “$1,177” | “$7,059” |
| 90 min integration session | “9” | “90837” | “2” | “$221” | “$3,971” |
ICER review of MDMA-assisted psychotherapy for PTSD: exploratory budget impact
ICER review of esketamine for treatment-resistant depression: cost-effectiveness, observation costs, and budget impact
U.S. cost-effectiveness of esketamine for treatment-resistant depression, including observation costs
“Our estimate of the total cost of esketamine provision includes costs of the medication itself, physician visits, and medical assistant observation during the two hours after each dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“This cost increase was driven largely by the cost of esketamine itself ($16,352), with smaller contributions from physician/medical assistant service costs ($2,062) and patient time costs ($2,074).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Base case ICERs were $237,111/QALY (societal) and $242,496/QALY (healthcare sector).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Cost-effectiveness of first-line drugs for GAD: UK decision model
“A decision-analytic model in the form of a decision tree was constructed to compare the costs and QALYs of six drugs used as first-line pharmacological treatments in people with GAD (duloxetine, escitalopram, paroxetine, pregabalin, sertraline and venlafaxine extended release [XL]) and 'no pharmacological treatment'.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“It also resulted in the lowest costs and highest number of QALYs among all treatment options assessed. Its probability of being the most cost-effective drug reached 75 % at a willingness-to-pay threshold of £20,000 per extra QALY gained.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Budget impact model
Approach and framework
No evidence found.
Perspective and time frame
No evidence found.
Epidemiology and eligible population inputs
No evidence found.
Cost assumptions
No evidence found.
Model outcomes
No evidence found.
Results
Base case
No evidence found.
Scenario analyses
No evidence found.
Budget impact model discussion
No evidence found.